Icatibant

Product description

is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. HAE (hereditary angiodysplasia)

Specifications

CAS Registry Number	130308-48-4
Categories	BiopharmaceuticalsBiopharmaceuticals (general category); APIs (Active Pharmaceutical Ingredients)Peptides
Sales markets	Western Europe; Eastern Europe; Asia; North America
Supplied from	China

More products from Chengdu Shengnuo Biopharm Co Ltd

Bivalirudin

Use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty .Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the ...

More info

Liraglutide

Diabetes mellitus,
Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetesLabel,2. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous t...

More info